WELCOME TO AVIADOBIO
At AviadoBio our mission is to transform the lives of patients living with and suffering from neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Our industry-leading science and technology is based on pioneering research from King’s College London and the UK Dementia Research Institute, co-founded by Prof. Christopher Shaw, Dr. Youn Bok Lee and Dr. Do Young Lee and is supported by leading life sciences investors.
We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products.
AN UNMET MEDICAL NEED
Neurological diseases are the single largest cause of disability worldwide and the second leading cause of mortality*. Recent successes in genetic medicine have demonstrated its great promise in treating previously untreatable, life-threating neurological diseases.
AviadoBio’s industry-leading team is pioneering novel applications of gene therapies to slow, arrest, prevent and potentially reverse neurodegenerative diseases.
Our unique, neuroanatomy-led approach to treating disease is designed to maximize therapeutic potential. We deliver our gene therapies to where we believe they will provide the most benefit to patients.